Latest Headlines

Does Anemia Protect Children From Malaria?

It is well known that sickle cell trait can protect carriers from developing malaria; yet iron deficiency anemia offers a greater protective effect against malaria than sickle cell trait, according to research published in...

Online Exclusive

Is It Too Soon to Celebrate the Cancer Death Rate Decline?

Earlier this year, the American Cancer Society reported the biggest one-year decline in cancer mortality ever recorded from 2016 to 2017. While fewer deaths...

Trump Administration Fetal Tissue Restrictions Disrupt Research

A recent decision by the Trump administration to limit funding for research using fetal tissue is changing scientists’ research paths and disrupting research into...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL

Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...

Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline...

Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...

David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML

Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...

Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis

Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...

On Location

ER-Based Protocol Improves the Accuracy of von Willebrand Disease Testing in Young Patients With Heavy Menstrual Bleeding

Watch our interview with Megan C. Brown, MD. Researchers at Children’s Healthcare of Atlanta (CHOA) have...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish...

Time-Limited Acalabrutinib Combination Has “Encouraging” Response Rates in Previously Untreated Chronic Lymphocytic Leukemia

Watch our interview with Benjamin Lampson, MD. Preliminary results from a trial presented at the 2019...

Adding Navitoclax to Ruxolitinib in Ruxolitinib-Refractory Myelofibrosis Leads to Improvements in Spleen Volume, Symptom Burden

Watch our interview with Jacqueline Garcia, MD. More than one-third of patients with myelofibrosis (MF) who...

KTE-X19: A CAR T-Cell Option for Mantle Cell Lymphoma?

According to results from the ZUMA-2 trial presented at the 2019 ASH Annual Meeting, 93%...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
12,700SubscribersSubscribe

ALCYONE Update: Adding Daratumumab to VMP Improves Survival in Transplant-Ineligible Myeloma

In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to bortezomib, melphalan, and prednisone (VMP)...

Lenalidomide Treatment Delays Progression From Smoldering to Symptomatic Myeloma

Observation is the standard approach to managing most patients with smoldering multiple myeloma (MM), but results from a phase III study suggest that early...

Early Intensification of Intrathecal Chemotherapy Reduces Risk of Relapse in Pediatric ALL

Two additional doses of intrathecal therapy early during induction treatment for children with newly diagnosed acute lymphocytic leukemia (ALL) who were at increased risk...
The Society Pages

Stephen Hahn Confirmed as FDA Commissioner, Beth Shaz Becomes AABB President, and more

Stephen Hahn Confirmed as FDA Commissioner The U.S. Senate voted 72−18 to confirm Stephen Hahn, MD, as the FDA’s new commissioner. President Donald Trump nominated...

Acalabrutinib Approved for CLL Under New International Collaboration

The FDA granted a supplemental approval to acalabrutinib for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Acalabrutinib...